7 employees
Refuge Biotechnologies therapeutic company focused on gene editing and genetic engineering of immune cells for cancer immunotherapy.
2015
$8.9M
from 2 investors over 2 rounds
Refuge Biotechnologies raised $8.9M on January 1, 2016
Investors: ShangBay Capital and 3E Bioventures Capital